Hi MUTOMBO,
Following
the recent news of Epizyme’s first patient enrolled in their clinical
trial of
EPZ-6438, an inhibitor of EZH2, we caught up with Executive VP
& CSO Bob Copeland
to find out what was going on behind the scenes
at this exciting time.
"Our
DOT1L inhibitor for use in MLL-r leukemia is in phase I now in a dose
escalation
stage and likewise our EZH2 inhibitor, 6438, which just
recently started a phase I
trial in non-Hodgkin lymphoma patients. We’re
very excited about these because
they represent, to the best of our
knowledge, the very first and second HMT inhibitors
to ever go into
clinical trials"
Bob was asked what’s been going on within Epizyme at the moment and also what
he feels has led to their success so far.
"It's
been a very exciting time at Epizyme; the discovery and the development
data are all falling into place very nicely and now we're seeing the
transition of
that into the clinic."
He also goes into much more detail about their company strategy and their
continuing involvement with the EpiCongress series.
“Hearing
what other thought-leaders are thinking about, sharing learnings
and
experiences with our other industrial colleagues as well as our academic
colleagues - it's been fantastic.”
The entire interview has been published as a PDF so that you can download your
own copy here
. Bob is one of 19 leaders on the speaker panel of EpiCongress London,
19-21 November 2013.
He will expand on the challenges of epigenetic drug development
and
give you exclusive data on Epizyme’s first clinical candidate molecule.
He is joined by speakers from the likes of: AstraZeneca, GSK, UCB Pharma, Eli Lilly, 4SC,
Pfizer, Johnson & Johnson, Astex Pharmaceuticals, Domainex, Novartis & more.
I hope you find the interview interesting and hope to see you in on site at EpiCongress
London in November.
Best wishes,
Zardia
Zardia Swift
Senior Program Director
Hanson Wade
| 
No comments:
Post a Comment